MagStim Rapid2 Transcranial Magnetic Simulation for Primary Progressive Aphasia

N/A

Waitlist Available

Led By Michelle Tsang, MD

Research Sponsored by University of Manitoba

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up one week pre- and one week post-rtms treatment

Awards & highlights

No Placebo-Only Group

Summary

This trial will investigate whether rTMS can improve language functioning in people with primary progressive aphasia-logopenic variant.

Eligible Conditions

Primary Progressive Aphasia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ one week pre- and one week post-rtms treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~one week pre- and one week post-rtms treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and one week pre- and one week post-rtms treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in score on the Druks and Masterson Naming Task

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Repetitive Transcranial Magnetic Stimulation (rTMS)Experimental Treatment1 Intervention

30 sessions of high-frequency (10Hz) repetitive stimulation applied over the posterior region of the left superior temporal gyrus in patients with logopenic primary progressive aphasia (PPA-L) using a MagStim Rapid2 Transcranial Magnetic Simulation machine.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

MagStim Rapid2 Transcranial Magnetic Simulation

2022

N/A

~30

Do I qualify?Apply below to find out